ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO230

Predicting Liberation from Continuous Kidney Replacement Therapy in Critically Ill Patients Using a Machine Learning Model

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Kashani, Kianoush, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Alfieri, Francesca, U-Care Medical s.r.l, Torino, Italy
  • Ancona, Andrea, U-Care Medical s.r.l, Torino, Italy
  • Zappalà, Simone, U-Care Medical s.r.l, Torino, Italy
Background

Continuous renal replacement therapy (CRRT) is utilized in nearly 14% of critically ill patients. Currently, there are no standardized practice guidelines to wean CRRT, apart from clinicians' discretion, as per the KDIGO guidelines. This study aims to develop and validate a model to predict successful CRRT liberation.

Methods

For this single-center, retrospective cohort study, we used data from 661 adult patients connected to 668 disinct ICU stays from MIMIC-IV dataset who received CRRT between 2008 to 2019.
CRRT liberation was defined as renal replacement therapy (RRT)-free survival within seven days after the liberation. We randomly divided the cohort into derivation (70%) and validation sets [KK1] (30%). The outcomes were successful CRRT liberation vs. unsuccessful CRRT liberation and/or death. A multiclass decision tree model was developed and internally validated.

Results

The final cohort included 668 ICU stays requiring CRRT, among them 266 (39.8%) were successfully liberated from CRRT, 265(39.7%) had unsuccessful CRRT liberation, and 137(20.5%) died while on CRRT.
The auROC of the model reflects its ability to discriminate between successful and unsuccessful liberation, varying from 0.797(CI 95% 0.743, 0.864) to 0.739(CI 95% 0.700, 0.810) when the model is activated at the time of CRRT liberation up to 12 hours later. Moreover, the model outputs a probability of mortality within seven days from the CRRT discontinuation, achieving auROCs from 0.746 (CI 95% 0.682, 0.861) to 0.861(CI 95% 0.795, 0.944) moving forward over time.

Conclusion

The model is designed to be used by clinicians at the time of CRRT liberation and can be consulted up to 12 hours after the discontinuation.
This validated model could be integrated into the clinical practice with the aim of assisting the decision-making related to the CRRT liberation in critically ill patients with AKI hospitalized in intensive care units, facilitating a timely reinstitution of CRRT where needed and ensuring better patient outcomes.

Funding

  • Commercial Support – U-Care Medical s.r.l.